AQP4 and myeloid sarcoma: We therefore profiled BA metabolism in NMOSD and MS to determine diagnostic utility.<h4>Methods</h4>We enrolled 112 NMOSD patients (32 AQP4-IgG seronegative, 80 AQP4-IgG seropositive), 50 MS patients, and 66 healthy controls.